The Phase 3 study is designed to bridge data collected from the vaccine efficacy trial conducted in India to the U.S. population
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
A growing number of studies have shown the benefit of a third dose of Covid-19 vaccine in immunocompromised subjects
The 462,000 square foot state-of-the-art building targeting LEED Zero certification and is designed to be the most sustainable commercial lab building in Cambridge
saRNA is a new platform for the development of medicines and vaccines which uses similar technology to mRNA but with the added ability to self-amplify, thereby expressing proteins for longer, resulting in higher protein levels per dose level
In the final analysis of Phase 3 COVE study data, SPIKEVAX showed 93% efficacy, with the efficacy remaining durable through six months after the administration of the second dose
Everest gains access to a clinically validated mRNA platform and a potentially “best-in-class” mRNA COVID-19 vaccine with full technology transfer
The trial will be conducted across eight sites in Maharashtra
Blood samples were collected from 114 healthcare workers who received Covaxin in Chennai from February to May 2021
The company has to approach the DCGI for approval to commence the trials
Subscribe To Our Newsletter & Stay Updated
